These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 16465373

  • 1. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
    Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, Kunz A, Hamann PR, Sridharan A, Jones S, Discafani C, Damle NK.
    Int J Oncol; 2006 Mar; 28(3):675-84. PubMed ID: 16465373
    [Abstract] [Full Text] [Related]

  • 2. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 3. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK, Frost P.
    Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
    [Abstract] [Full Text] [Related]

  • 4. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK.
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [Abstract] [Full Text] [Related]

  • 5. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
    Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, Harrop R, Kunz A, Hamann PR, Marquette K, Dougher M, DiJoseph JF, Damle NK.
    Int J Oncol; 2008 Jan; 32(1):221-34. PubMed ID: 18097562
    [Abstract] [Full Text] [Related]

  • 6. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.
    Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK.
    Cancer Chemother Pharmacol; 2008 May; 61(6):1027-35. PubMed ID: 17668210
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E.
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
    Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR.
    J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Shochat D, Mountain A.
    Bioconjug Chem; 2005 Aug; 16(2):354-60. PubMed ID: 15769089
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.